الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 144 |  |  |
| | | from | 144 | | |
Abstract
Pharmacogenomics is a rapidly growing research field concerned with the study of variations of DNA and RNA as related to drug response as well as its relevance to disease. It opens up the possibility of individualised medicine, allowing clinicians to predict who will get the disease, whether it will be a short benign or long debilitating course and who will get complications from the disease. More importantly, it will allow clinicians to better tailor treatment options for patients, avoiding drug toxicities and achieving long-term remission for patients. It holds much promise for chronic debilitating diseases like psoriasis.
During the last decade, significant advances were made in understanding the genetic basis of psoriasis and several genes have been identified to participate in its pathogenesis and course.
Pharmacogenomic data are available for most conventional agents that are used to treat psoriasis, including methotrexate, retinoids, vitamin D derivatives, biological therapy, cyclosporine, coal tar, and topical corticosteroids.
Although topical steroids are the most commonly drugs used for treatment of psoriasis, there has been very limited pharmacogenetic studies that predict response to topical steroids. The only available study showed that variation in the expression and regulation of DME gene in the skin may be a determinant of individuality in response to topical steroids of psoriasis. Pharmacogenetic studies are also limited for other treatment options like narrow-band UVB therapy and retinoids.